Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 19, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 19, 2025 -- For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall survival versus placebo + ENZA, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.

Neeraj Agarwal, M.D., from the Huntsman Cancer Institute at the University of Utah in Salt Lake City, and colleagues reported final overall survival (OS) data among patients with mCRPC unselected for HRR gene alterations who had improved radiographic progression-free survival with TALA + ENZA versus placebo + ENZA as first-line treatment in the phase 3 TALAPRO-2 trial.

A total of 805 patients were randomly assigned: 402 and 403 to TALA + ENZA and placebo + ENZA, respectively. At the data cutoff (Sept. 3, 2024), 52 and 60 percent of patients in the TALA + ENZA and placebo + ENZA arms, respectively, had died. The researchers found that the hazard ratio for OS was 0.796 (95 percent confidence interval, 0.661 to 0.958) for TALA + ENZA versus placebo + ENZA, with a median OS of 45.8 and 37.0 months, respectively. In patients who were HRR-deficient and in those who were HRR-nondeficient/unknown, OS favored TALA + ENZA versus placebo + ENZA (hazard ratios, 0.549 [95 percent confidence interval, 0.364 to 0.826] and 0.878 [95 percent confidence interval, 0.713 to 1.080], respectively). Updated radiographic progression-free survival data favored TALA + ENZA versus placebo + ENZA, consistent with the primary analysis (hazard ratio, 0.667; 95 percent confidence interval, 0.551 to 0.807).

"TALA + ENZA demonstrated a statistically significant and clinically meaningful improvement in OS versus standard-of-care ENZA," the authors write.

Several authors disclosed ties to Pfizer, which manufactures talazoparib.

Abstract

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-20 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords